ABSTRACT BACKGROUND There has been conflicting clinical evidence as to the influence of female sex on outcomes after
T ranscatheter aortic valve replacement (TAVR) is the new standard of care for patients with symptomatic aortic stenosis who are deemed to have high or prohibitive surgical risk, with >80,000 procedures performed to date in >40 countries worldwide (1, 2) . The current evidence with regard to the impact of sex on outcomes in TAVR is insufficient and conflicting, with some studies reporting improved mid-to long-term survival in women (3) (4) (5) and other studies demonstrating similar or worse survival compared with men (6, 7) . This remains an overall unresolved and poorly described issue that has significant implications with regard to patient selection for this procedure. Therefore, to evaluate the influence of sex on clinical outcomes in high-risk patients undergoing TAVR, we performed a collaborative meta-analysis of individual patient-level data.
METHODS STUDY COHORT. We conducted searchers of the Cochrane Controlled Trials Registry and MEDLINE
and Embase databases for reports published from January 2002 through June 2014 using the following pre-defined search terms: transcatheter aortic valve implantation/replacement and outcome or gender or sex. We restricted our analysis to published data.
References from reviews and selected reports were also examined for potential relevant citations.
No language restrictions were applied. Studies were selected by 2 independent reviewers (S.A.O., M.-C.M.).
We restricted our analysis to trials that met all of the following inclusion criteria: 1) inclusion of patients with severe aortic valve stenosis undergoing TAVR via the transfemoral, transapical, transaortic, transcarotid, or transsubclavian approach; 2) either a single-group cohort or a controlled comparison between TAVR and surgical aortic valve replacement through random or nonrandom allocation; and 3) available data on at least short-term (30-day or inhospital) and 1-year all-cause mortality. Randomized controlled trials, registries, and pre-specified subgroups of studies reporting TAVR data were considered for analysis. Full-text articles were included.
Exclusion criteria were duplicate reports, unpublished meeting abstracts and studies with <200 patients, and studies that did not perform multivariable adjustment. The quality of randomized controlled trials included in the meta-analysis was assessed for descriptive purpose using the Jadad score for randomized controlled trials and the quality of nonrandomized studies (8) using the Newcastle-Ottawa Scale for cohort studies (Online Table 1 Cox multivariate analysis including all variables with p values <0.05 in each univariate analysis were used.
Results are presented as hazard ratios with 95% confidence intervals (CIs). The p value threshold for statistical significance was set at 0.05. Analyses were conducted using SPSS version 21 (SPSS, Inc., Chicago, Illinois).
RESULTS
Our search identified 520 reports (Figure 1) , of which 508 were excluded after abstract screening. Of the 17 full-text reports assessed, 5 studies were excluded because they contained patient data that overlapped with our selected studies (4,6,10-12), 3 were excluded because of small sample sizes (n < 200) (13) (14) (15) , and 3 were excluded because the investigators did not perform multivariate adjustment and/or reported 30-day follow-up only (16) (17) (18) . Finally, 6 studies were selected and the principal investigators contacted (3, 5, 7, (19) (20) (21) . Five investigators answered positively, leaving a total of 5 studies and their registry data, comprising a total of 11,310 patients, for inclusion in the analysis (3, 7, (19) (20) (21) . Table 1 . Table 1 .
The majority of the overall cohort underwent TAVR via the transfemoral approach, followed by the transapical and transsubclavian approaches. The transfemoral approach was more common in women than in men. Balloon-expandable devices were used more frequently than self-expandable valves in the overall cohort, and a higher proportion of women than men received balloon-expandable valves.
Clinical outcomes are listed in Table 2 . In the whole group, procedural success was achieved in 97% of patients, irrespective of sex. There was no difference in the incidence of valve migration or embolization, conversion to conventional surgery, or procedurerelated death. There was, however, a higher rate of In the Cox model for all-cause mortality, the adjusted hazard ratio for female sex was 0.79 (95% CI:
0.73 to 0.86; p < 0.001). The independent predictors of late mortality are listed in Table 3 .
Female sex was consistently associated with improved survival regardless of valve type and route of access when subanalyses were performed in these subgroups (Online Figure 1) .
In a subanalysis comparing the predictors of mortality between women and men, both sexes shared the predictors body mass index, pulmonary disease, creatinine clearance, aortic incompetence postimplantation (grade >2), and a nonfemoral approach (Online Table 4 ). However, age was a predictor of mortality in men but not in women. Major bleeding at 30 days was significantly more frequent in female patients, an observation that has also been reported in some other studies (3,6);
however, this finding has not been consistent across all studies (7, 12) . Again, the likely mechanisms for this are the lower body surface area and older age of female patients. These data are comparable to peri-percutaneous coronary intervention bleeding data, in which female sex is a significant risk factor (24) .
To our knowledge, this is the first analysis to demonstrate a significantly higher rate of stroke in women undergoing TAVR (Central Illustration). This is a somewhat surprising finding, and it is difficult to explain given the lower baseline vascular risk in women. We also demonstrated that this in- Values are n (%). 
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Women's survival advantage throughout the follow-up period is depicted.
Second, although women were older than men, they had a lower baseline cardiovascular risk profile and fewer comorbidities. Although the sex difference in mortality outcomes remained significant after adjustment for these demographic, procedural, and clinical differences, the potential impact of these factors and other unidentified confounders cannot be underestimated. Furthermore, the recognized longer life expectancy described in women contributes to this explanation.
Third, women had a significantly lower incidence of moderate to severe paravalvular aortic incompetence post-procedurally than men, probably because of more frequent undersizing in men due to larger annular sizes. This appeared to occur more exclusively with balloon-expandable valves. Post-TAVR aortic regurgitation has been shown to be associated with increased mortality (20, 21, 25) .
Finally, it has been demonstrated that women adapt differently than men with aortic stenosis, with higher levels of interstitial fibrosis in men (26) multinational, multicenter, randomized and nonrandomized real-world studies. Also, it was adequately powered to assess mortality outcomes. Our study, however, was subject to selection bias, as we were able to include data from only 5 of the 6 studies identified by our systematic search strategy. Because this study was an analysis of a global population, we could not perform a sensitivity analysis. With regard to the studies included, individual study effect was adjusted for by introducing the study as a covariate.
Results with and without studies' factors were similar, and therefore we may conclude that the characteristics of the studies do not modify the results.
CONCLUSIONS
This is the largest study to date of sex differences in outcomes after TAVR. Women had significantly better late survival despite higher rates of major bleeding, vascular, and stroke complications. Given the natural longer life expectancy of women, TAVR should be even more cost effective in women than in men. If it is confirmed that conventional surgery has worse outcomes in women than in men, these findings may have significant implications for future patient selection for TAVR. However, the definitive answer will be provided by ongoing trials comparing conventional surgery with TAVR in medium-risk pa-
tients, which may demonstrate that women can benefit earlier from TAVR than men. TRANSLATIONAL OUTLOOK: Future studies should be directed toward developing advances in device technology and patient selection to reduce the risk for procedural morbidity associated with TAVR, particularly for women.
